Genome-wide DNA methylation analysis showed that bortezomib treatment resulted in hypomethylation of the NOXA gene; however, further in vitro studies demonstrated that administration of methyltransferase inhibitor decitabine (DAC) along with bortezomib overcame bortezomib resistance in relapsed/refractory MCL [177]. The gene discussed is PMAIP1; the disease is mantle cell lymphoma.